Patents Assigned to Agouron Pharmaceuticals, Inc.
  • Patent number: 7070071
    Abstract: A dispensing apparatus for a liquid product, the apparatus comprising a) a housing (2) or frame (3), b) a receptacle (4) for the liquid with a feed nozzle (4a) arranged substantially stationary with respect to the housing or frame, c) a dosing chamber (11) having an orifice (11a), d) a mechanism arranged to allow at least ejection of liquid through the orifice and e) a through passage (7) arranged to allow the ejected liquid to pass in a direction different from the feed nozzle or opening.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: July 4, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bohdan Pavlu, Hans Himbert, Christian Péclat, Emmanuel Gremion, Daniel Siegfried, Alain Saurer, Joel Fontannaz
  • Patent number: 7063687
    Abstract: An eye fluid applicator comprising a) a hand grip part having a distal end and a proximal end, the distal end and the proximal end defining a axis therebetween and a distal direction and a proximal direction along said axis, b) a container, or a seat for a container, having a bottle part and a delivery orifice for delivery of a stream or drops, the orifice defining a fluid delivery axis and a fluid delivery direction, along said axis, from the bottle through the orifice, the container being arranged with its orifice closer to the proximal end than the distal end, and c) an eye cup part having a rim and a cavity, the rim defining a contact plane, a contact axis normal to said contact plane and a contact direction, along said contact axis, from the cavity towards the rim, the eye cup being arranged at the orifice and the proximal direction of the hand grip and the contact direction of the eye cup forming an acute angle therebetween.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: June 20, 2006
    Assignee: Agouron Pharmaceuticals , Inc.
    Inventors: Maria Benktzon, Henric Bjarke, Carl-Göran Crafoord, Hans Himbert, Stig Mannberg, Ann-Marie Svensson, Jonas Törnsten
  • Patent number: 7053107
    Abstract: Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Grant
    Filed: December 15, 2003
    Date of Patent: May 30, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Allen J. Borchardt, Robert Steven Kania, Cynthia L. Palmer
  • Patent number: 7045528
    Abstract: The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
    Type: Grant
    Filed: March 9, 2004
    Date of Patent: May 16, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Michael Collins, Stephan Cripps, Judith Deal, Robert Steven Kania, Jihong Lou, Mingying He, Cynthia Louise Palmer, William Henry Romines, III, Ru Zhou
  • Patent number: 7045646
    Abstract: This invention describes a convenient method for the preparation and use of a ruthenium catalyst for a chiral reduction of ketones and imines.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: May 16, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Steven P. Tanis, Bruce Evans
  • Patent number: 7022846
    Abstract: Metabolites of a matrix metalloproteinase inhibitor prinomastat and their synthesis. These metabolites are: (3S)-N-hydroxy-4-(4-((1-oxy-pyrid-4-yl)oxy)benzenesulfonyl)-2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide (M6); (3S)-2,2-dimethyl-1,1-dioxo-4-[4-(1-oxy-pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M7); (3S)-2,2-dimethyl-4-[4-(1-oxypyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M8); (3S)-2,2-dimethyl-1,1-dioxo-4-[4-(pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M2); and (3S)-2,2-dimethyl-4-[4-(pyridin-4yloxy)-benzenesulfonyl)-thiomorphpline-3-carboxylic acid amide (M3).
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: April 4, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Michael A. Ouellette, Barbara C. M. Potts, Jayaram K. Srirangam, Anthony R. Tibbetts, Kanyin E. Zhang
  • Patent number: 7008953
    Abstract: 3,5 disubstituted indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Grant
    Filed: June 10, 2004
    Date of Patent: March 7, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Susan Elizabeth Kephart, Indrawan James McAlpine, Siegfried Heinz Reich
  • Patent number: 7001912
    Abstract: Beta-carboline hydroxamic acid compounds represented by formula (I) are described. The beta-carboline hydroxamic acid compounds and compositions containing those compounds may be used to inhibit or modulate the activity of HIV integrase enzyme and to treat HIV integrase-mediated diseases and conditions.
    Type: Grant
    Filed: January 26, 2004
    Date of Patent: February 21, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Atsuo Kuki, Xinqiang Li, Michael Bruno Plewe, Hai Wang, Junhu Zhang
  • Patent number: 6995142
    Abstract: Peptido and peptidomimetic compounds of the formula: wherein the formula variables are as defined in the disclosure, advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as RVP. Intermediates and synthetic methods for preparing such compounds are also provided.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: February 7, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Peter Scott Dragovich, Stephen Evan Webber, Thomas Jay Prins, Ru Zhou, Joseph Timothy Marakovits, Theodore O. Johnson, Jr.
  • Patent number: 6995171
    Abstract: The invention relates to compounds of the formulas 1 and 2 and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein X, R1 and R11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas 1 and 2 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formulas 1 and 2.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: February 7, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Christopher Autry, Michael J. Luzzio, Matthew A. Marx
  • Patent number: 6989384
    Abstract: Compounds of the formula: where the formula variables are as defined in the disclosure, advantageously inhibit or block the biological activity of the picomaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as RVP. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Grant
    Filed: July 23, 2003
    Date of Patent: January 24, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Ye Hua, Hiep The Luu, Fora P. Chan, Theodore O. Johnson, Jr., Siegfried Heinz Reich, Donald James Skalitzky, Yi Yang, Thomas F. Hendrickson, Shao Song Chu, Brian Walter Eastman
  • Patent number: 6977302
    Abstract: The invention provides compounds of formula I, R1—OP(O)(OH)2??I wherein R1 represents the non-hydroxy portion of a triazole antifungal compound of the type comprising a tertiary hydroxy group; or a pharmaceutically acceptable sat thereof. The compounds of the invention are useful in the treatment of fungal infections, and have good aqueous solubility.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: December 20, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stuart Green, Peter T. Stephenson, Martha H. Murtiashaw, Charles W. Murtiashaw
  • Patent number: 6974834
    Abstract: This invention relates to a process for the synthesis of enantiomerically enriched (1S,4R) 1-acetoxy-4-hydroxycyclopent-2-ene of Formula I, a compound useful as an intermediate in the synthesis of prostaglandins and prostanoids.
    Type: Grant
    Filed: January 7, 2004
    Date of Patent: December 13, 2005
    Assignee: Agouron Pharmaceuticals Inc.
    Inventor: Kevin Edward Henegar
  • Patent number: 6967198
    Abstract: Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3 and R4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.
    Type: Grant
    Filed: January 9, 2004
    Date of Patent: November 22, 2005
    Assignee: Agouron Pharmaceuticals Inc.
    Inventors: Suzanne Benedict, Michael Bennett, Sacha Ninkovic, Min Teng, Yuanjin Rui, Fen Wang, Yong Wang, Jinjiang Zhu
  • Patent number: 6964957
    Abstract: Pyrazole compounds represented by the formula: are described. The pyrazole compounds and pharmaceutical compositions containing them may be used in inhibiting ERAB or HADH2 activity and in treating ERAB, HADH2 or amyloid-? mediated diseases and conditions.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: November 15, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Melwyn A. Abreo, Jerry J. Meng, Charles S. Agree
  • Patent number: 6953858
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: October 11, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stacie S. Canan Koch, Therese N. Alexander, Mark Barvian, Gary Bolton, Frederick Earl Boyer, Jr., Benjamin J. Burke, Tod Holler, Tanya M. Jewell, Vara Prasad Josyula, David J. Kucera, Maria Angelica Linton, Jeffrey J. Machak, Lennert J. Mitchell, Jr., Sean T. Murphy, Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Michael Melnick
  • Patent number: 6933312
    Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R4, n W, X and Y are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
    Type: Grant
    Filed: September 23, 2003
    Date of Patent: August 23, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: David A. Price, Matthew D. Selby, Paul A. Stupple
  • Patent number: 6919461
    Abstract: Indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: July 19, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Siegfried Heinz Reich, Ted Michael Bleckman, Susan Elizabeth Kephart, William Henry Romines, Michael B. Wallace
  • Patent number: 6906198
    Abstract: Peptido and peptidomimetic compounds of the formula: wherein the formula variables are as defined in the disclosure, advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as RVP. Intermediates and synthetic methods for preparing such compounds are also provided.
    Type: Grant
    Filed: January 5, 1999
    Date of Patent: June 14, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Peter Scott Dragovich, Stephen Evan Webber, Thomas Jay Prins, Ru Zhou, Joseph Timothy Marakovits, Theodore O. Johnson, Jr., Jayashree Girish Tikhe
  • Patent number: 6903132
    Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: June 7, 2005
    Assignees: Agouron Pharmaceuticals, Inc., Pfizer Inc.
    Inventors: Mark B. Anderson, Lance Christopher Christie, Quyen-Quyen Thuy Do, Jun Feng, Yufeng Hong, Haitao Li, Ved P. Pathak, Ranjan Jagath Rajapakse, Eric T. Sun, Eileen Valenzuela Tompkins